Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Nov 3, 2022, after the close
10-Q filed Nov 3, 2022, 34 days after period end · 0001558370-22-016266
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $22.41M | $21.54M | $18.39M | $20.86M |
| Net Income | -$19.04M | -$20.95M | -$14.17M | -$11.49M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.11 |
| -$0.12 |
| -$0.08 |
| -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
